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Objective. Human papillomavirus (HPV) infections remain a leading cause of mortality worldwide. In the
U.S. strategies via screening and vaccination prevent HPV-associated cervical neoplasms, but consume im-
mense healthcare costs. The spice component curcumin has potent anticancer and antiviral properties,
which have been difficult to harness as a treatment, due to its poor systemic bioavailability. This project
tests the possibility of developing a curcumin-based therapy for cervical cancer.
Methods. Using four HPV(+) cervical cancer cell lines and normal fibroblasts we first tested the selectivity
and potency of curcumin in eliminating HPV(+) cells. Subsequently, we developed a curcumin-based cervi-
cal cream and tested its efficacy in eliminating apposed HPV(+) cells and also its possible side effects on the
vaginal epithelium of healthy mice.
Results. Curcumin selectively eliminates a variety of HPV(+) cervical cancer cells (HeLa, ME-180, SiHa,
and SW756), suppresses the transforming antigen E6, dramatically inhibits the expression of the
pro-cancer protein epidermal growth factor receptor (EGFR), and concomitantly induces p53. Additionally,
Vacurin, a uniform colloidal solution of curcumin in a clinically used amphipathic vaginal cream, eliminates
apposed HeLa cells while suppressing the expression of EGFR. In mice, daily intravaginal application of
Vacurin for three weeks produced no change in body weight and when the mice were sacrificed, the vaginal
tract epithelium showed no Vacurin-evoked adverse effects.
Conclusion. We have developed a curcumin-based vaginal cream, which effectively eradicates HPV(+)
cancer cells and does not affect non-cancerous tissue. Our preclinical data support a novel approach for the
treatment of cervical HPV infection.© 2012 Elsevier Inc. All rights reserved.d the Center for Developmental
ollege of Staten Island, Staten
nerjee).
rights reserved.Introduction
Cervical cancer is a leading cause of cancer death amongst females
worldwide, of which the human papillomavirus (HPV) is the main
etiologic risk factor [1]. By the age of 50, 75–80% of sexually active
women have acquired HPV at some point in their lifetime, making it
the most common sexually transmitted disease in the United States
[2]. In developed countries, cervical cancer screening programs have
146 P.R. Debata et al. / Gynecologic Oncology 129 (2013) 145–153been effective in reducing cancer mortality [3]. But the annual cost to
treat HPV-associated pre-cancers is in the order of billions of dollars
in the U.S. [4]. Precancerous lesions of the cervix can be identified
early and treated. In women of reproductive age, loop electrosurgical
excision procedure (LEEP) is the most common strategy used to treat
high-grade dysplasia. Though LEEP is a very effective treatment
option, it comes with some risk. Cervical incompetence and preterm
delivery are potential consequences that affect future obstetrical out-
comes [5,6]. In a promising recent report, using the Toll-like receptor
7 agonist imiquimod in a phase II clinical trial, regression of CIN 2–3
lesions and HPV infection were demonstrated with 16 weeks of
intravaginal application of this compound [7] Though promising, not
all HPV associated lesions were cleared in this study. Therefore, a uni-
versally effective treatment for cervical HPV infection does not exist.
The introduction of the two prophylactic HPV vaccines, Cervarix® or
Gardasil® [8] offers promise to prevent the most common oncogenic
HPV types 16/18-associated cervical lesions, but efficacy is achieved
only in HPV-naïve patients [3] as the vaccines are not therapeutic.
Additionally, in developing nations with limited economic resources
or poor healthcare infrastructure, vaccination programsmay not be fea-
sible. Thus, despite significant advances in prevention, screening and
treatment, cervical HPV infection remains a major cause of morbidity
and mortality of women worldwide. Therefore, examining agents har-
boring antiviral and/or antitumor properties against HPV-associated
lesions remains as an important focus.
Curcumin, a yellow pigment from the root of Curcuma longa linn is
a natural inexpensive component derived from the Southeast Asian
spice turmeric. Clinical studies have demonstrated that oral adminis-
tration of curcumin is safe and well-tolerated with no significant tox-
icity and an acceptable blood chemistry profile [9–11], but its use is
limited by its low systemic bioavailability [12,13]. Nevertheless,
curcumin's potential role in cancer therapy continues to be investi-
gated in clinical trials for several types of cancer [9,10,14–16]. Exper-
iments in cell culture systems and animal models have established
curcumin's antitumor [14], anti-inflammatory [14], and anti-viral
properties [17–19]. Such studies have shown that curcumin treat-
ment of HPV-infected cells rapidly inhibits the expression of
HPV-E7, a key oncoprotein involved in tumor growth and malignant
transformation and also restores the levels of the cell cycle regulators
p53 and retinoblastoma protein (Rb) [17]. Like many other HPV pos-
itive cervical cancer cells, the cell lines used here HeLa, ME-180, SiHa,
and SW756 harbor the wild-type p53 protein [20,21]. Both cell cycle
inhibitors p53 and Rb are suppressed in most cancer cells, and ex-
pression of increased levels of these proteins has been linked to re-
gression of cervical cancer [22–24]. Therefore, any curcumin-evoked
induction in p53 and/or Rb could be effective in derailing the cells
from cell cycle and cancer growth. This is the first hypothesis that
has been tested in the current study.
Curcumin has been used to eliminate cervical cancer cells in lab-
oratory experiments, but its use in the treatment of cervical cancer
has had limited success, partially because of its low solubility in
water [12,13]. We postulate that intravaginal application of a
curcumin-based amphipathic cream may be a safe alternative with
the potential for improved efficacy. We demonstrate here that a col-
loidal mixture of curcumin in a vaginal cream is able to eliminate
juxtaposed cancer cells in culture without any adverse effect on the
lower reproductive tract in a mouse model.Materials and methods (see Supporting Information for details)
Animals
All animals were handled and used for surgery following an experi-
mental protocol approved by the Institutional Animal Care Committee
(IACUC) of the College of Staten Island (CUNY).Cell culture
Human dermal fibroblast cells (ATCC) were procured and cultured
using fibroblast growth supplements and 1% penicillin-streptomycin
(PS). HeLa (HPV-18 +), ME-180 (HPV-68+), SiHa (HPV-16+), and
SW756 (HPV-18+) cells [20,21,25–27] were obtained from ATCC
and cultured in Dulbecco's Modified Eagles Medium (DMEM)
containing 10% fetal bovine serum (FBS) and 1% PS.
Curcumin
(Please see Supporting Information for details on source and
solubilization).
Curcumin treatment and WST-1 assay
The general methods have been reported earlier [28,29]. Further
details have been included in the Supporting Information.
Western blot analysis
The general procedure has been reported in our earlier publica-
tions [28,29]. (Please see Supporting Information for details).
Immunofluorescence staining
The general procedure has been reported in our earlier publica-
tions [28,29]. (Please see Supporting Information for details).
Vaginal curcumin formulation
Intravaginal formulation containing 2%, 5%, 10% and 20% (w/w)
curcumin were prepared by mixing curcumin powder with a com-
mercially available topical oil-in-water cream base called Vanicream
(Pharmaceutical Specialties, Inc., Rochester, MN). These formulations
were named as Vacurin-2, Vacurin-5, Vacurin-10, and Vacurin-20,
respectively. Our tests showed that 5 g of Vacurin occupied a volume
of 5 ml. Therefore, in the rest of this report, we have expressed the
concentrations of curcumin in Vacurin as 20% (w/v). The two compo-
nents were thoroughly mixed using a spatula and the homogeneity of
the mixture was verified by visualizing curcumin fluorescence at
530 nm using a Leica Laser Confocal Scanning System (Exton, PA)
TCS SP2.
Toxicity tests for Vanicream and Vacurin-20 in mice
Three-month-old female mice in three groups were intravaginally
treated with intravaginal infusions of PBS, Vanicream or Vacurin-20.
Group#1 received PBS alone, Group#2 received Vanicream alone
and Group#3 received Vacurin-20. The mouse vaginal tract volume
was measured and observed to be around 10 μl. Therefore, approxi-
mately 10 μL of either PBS, Vanicream or Vacurin-20 were infused
using a fire-polished pasture pipette into the vagina every morning
at 9:30 AM. The applications were continued daily for two weeks
after which the body weight of each mouse was determined. To min-
imize variations in inflammation, mouse vaginal smears were moni-
tored and each mouse was euthanized at the first proestrus stage
following the last treatment [30]. Subsequently, the uterus-cervix
and vagina were dissected in its entirety as a single specimen, fixed
in 10% formalin, sectioned into sagittal sections, and stained with
hematoxylin and eosin (H&E) for histopathologic examination by a
pathologist (L.M.O).
Statistical analysis
Please see Supporting Information.
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Curcumin causes a decrease in cell viability as assessed by morphological
analysis as well as WST-1 assay
Cultured human cervical cancer cells of four clonal origins, HeLa,
ME-180, SiHa, and SW756, were efficaciously eliminated by
curcumin. Based on WST-1 assays, the IC50 concentrations were
17 μM (HeLa), 12 μM (ME-180), 51 μM (SiHa), and 21 μM (SW756),
respectively. In sharp contrast only high concentrations of curcuminFig. 1. Curcumin treatment eliminates HPV-antigen-containing cervical cancer cells. Curcumi
on fibroblast cells in culture. Fibroblast, HeLa, ME-180, SiHa, and SW756 cells were treat
carrier-treated and curcumin (30 μM) is shown for each of the cell lines. WST-1 assays
curcumin on the different cell lines used in the study. The IC50 value indicated in each gra(≥100 μM) caused a significant decrease in WST-1 activity in the pri-
mary human fibroblasts (Fig. 1).
Curcumin causes rapid suppression of Epidermal Growth Factor Receptor
(EGFR) and elevation of the cell cycle inhibitor p53
Discrete signaling proteins mediate transformation, survival, and
proliferation of various types of cancer cells. Curcumin disrupts sig-
naling or expression of a key signaling protein specific to a cancer
cell type rapidly, even before any cell degeneration is visible. Thus,n treatment (96 h) causes suppression of cervical cancer cell growth but has little effect
ed with carrier and different doses of curcumin for 96 h. A representative image for
were performed. The graphs represent the dose-dependent response for carrier and
ph was obtained from two experiments, each performed with triplicate samples.
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curcumin within 8 h of treatment [28,31]. Most notably, in these cer-
vical cancer cells, epidermal growth factor receptor (EGFR) is dramat-
ically suppressed by curcumin within 8 h (Fig. 2). Simultaneously,
curcumin treatment elicits elevated expression of the cell cycle inhib-
itor p53 (Fig. 2). A concomitant inhibition of serine-780 phosphoryla-
tion Rb, which inactivates this cell cycle inhibitor, was also observed
in the HeLa and ME-180 cells. The Rb levels were much higher and
P-S780-Rb/Rb ratio very small in the SiHa and SW756 cells to observe
any regulation of phosphorylation.
Curcumin causes suppression of the cell-transforming HPV antigen E6
Immunohistochemical analysis revealed detectable expression of
E6 in all four cervical cancer cell lines, HeLa, ME-180, SiHa, and
SW756, but not in the human fibroblast cells (Fig. 3a and Supplemen-
tary Fig. 1). Curcumin treatment caused a significant decrease in the
expression of E6 in all the four cell lines (Fig. 3b and Supplementary
Fig. 1). Similar experiments were also attempted using a wide range
of concentrations of a HPV 16 specific monoclonal anti-E7 antibody
(cat# Sc-6981, Santa Cruz Biotechnology, Santa Cruz, CA), but no im-
munocytochemical staining could be achieved.Fig. 2. Curcumin treatment of cervical cancer cells causes a dramatic inhibition of EGFR wi
vehicle alone or curcumin (50 μM) for 8 h. Western blotting of cell lysates revealed a dram
increase in p53 and a decrease in Rb phosphorylation in HeLa and ME-180 cells. (b) (i–iii)
carrier-treated demonstrate the decrease in EGFR, increase in p53, and decrease in phosphor
experiments (n=3). The numbers shown below the columns represent the lanes in the WCurcumin forms a smooth colloidal solution in the neutral vaginal
gel Vanicream
To enable topical application of curcumin in a form that could be
readily absorbed by the apposed cells, we tested the miscibility of
the hydrophobic molecule curcumin in the amphipathic vaginal gel
Vanicream. Up to 20% w/v, curcumin formed a uniform colloidal solu-
tion in Vanicream (named as Vacurin-20) as evidenced by an increase
in fluorescence intensity of a layer of the gel on a microscopic plate at
530 nm. Beyond 20% (w/v), solid curcumin particles remained and no
further increase in fluorescence intensity was observed (Supplemen-
tary Fig. 2a and b). Supplementary Fig. 2c shows the uniform yellow
color of Vacurin-20.
Cervical cancer cells apposed to Vacurin-20 are eliminated
To verify if topical application of Vacurin-20 could eliminate cancer
cells, Vacurin-2 (2% curcumin), Vacurin-5 (5% curcumin), Vacurin-10
(10% curcumin), and Vacurin-20 (20% curcumin) (100 mg of each)
were each placed on a porous (0.22 μm) membrane in an 8-mm tissue
culture insert, which was held within 1 mm from HeLa cells cultured in
a 35-mm well of a six-well tissue culture plate. The cells and theth concurrent induction of p53. (a) HeLa, ME-180, SiHa, and SW756 cells treated with
atic inhibition of EGF receptor expression. By contrast, curcumin treatment caused an
Quantification of band intensities, normalization to ß-actin, and expression as percent
ylation of Rb following curcumin treatment. Results were quantified from three discrete
estern blots shown in Fig. 2a.
Fig. 3. Curcumin treatment causes suppression of the HPV-16 E6 protein in the cervical cancer cells within 8 h. Immunostaining shows expression of the HPV-16 E6 protein in all
four cervical cancer cells but not normal human fibroblasts. (a) Curcumin treatment causes down regulation of the E6 protein in HeLa cells (Fig. 3a, upper panel). Nuclear
Hoechst33342 staining was used to visualize the cells. The merged images for E6 and Hoechst33342 staining are shown in the lower panel of Fig. 3a (immunostaining images
for other cell lines are shown in Supplementary Fig. 1). (b) The graph shows a quantitative analysis of E6, which is down regulated by curcumin treatment in the cervical cells
used in this study (Fig. 3b). Results presented were obtained from two independent experiments, each performed with triplicate wells of cells.
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juxtaposed to the membrane as well as those away from the insert
were analyzed by microscopy (Fig. 4a). Vacurin-5, Vacurin-10, and
Vacurin-20 caused increasing inhibition of cell number in the immedi-
ate vicinity (Fig. 4a and b). In Vacurin-20 treatment, the apposed cells
(juxtaposed to the membrane) and in the immediate vicinity were
completely eliminated. In contrast, cells at increasing distance from
the insert were much less affected by Vacurin and placing Vanicream
or solid curcumin on the membrane without the cream caused no cell
death at all (Fig. 4a).WST-1 assay performed on the entire well showed
a much smaller decrease in activity in Vacurin-20, which demonstrated
that Vacurin-20 acted only on cells that were closely apposed to the
cream (Fig. 4c).
Vacurin-20 treatment causes suppression of EGF receptor expression and
vaginal application of Vacurin-20 yields no detrimental effect
HeLa cells treated for 8 h with Vacurin-20 showed a significant
suppression of EGF receptor expression (Fig. 5a and b).Vanicream or Vacurin-20 (10 μl mouse) was applied daily to the
vaginal tract and cervix of adult C57BL6 female mice. After three
weeks of treatment, the Vacurin-20-treated mice appeared indistin-
guishable from Vanicream-treated and untreated controls in weight
(Fig. 5c). In a similar experiment with three mice in each group
treated with either intravaginal infusions of PBS or Vanicream or
Vacurin-20, the mice were then sacrificed and the lower reproductive
tract was removed and saggital sections of the tissue were stained
with H&E. The Vacurin-20-treated mice did not show any increased
inflammation compared to the PBS- or Vanicream-treated mice
(Fig. 5d and Table 1). The vaginal epithelium of the mice did not
show any ulceration, areas of necrosis, or micro-abscess formation.
The inflammation noted among the Vacurin-treated mice in the
epithelial and stromal regions were not more than that in the control
animals, which received either intravaginal PBS or Vanicream. One
mouse in the PBS treated group had grade 3 severe inflammation at
the distal segment of the vaginal tract, this was possibly due to
mechanical trauma during intravaginal infusion, otherwise, all groups
had similar histopathologies after vaginal infusion.
Fig. 4. Elimination of apposed cancer cells by Vacurin. (a) HeLa cells were cultured in a 12-well cluster plate and 50-mg of Vanicream alone or different formulations of Vacurin were
placed on a porous membrane in a tissue culture insert suspended 1 mm above the cultured cells for 72 h. (a and b) Cells juxtaposed to the membrane were eliminated, whereas
cells located further away were less affected. (c) Peripheral live cells dis-allow a dramatic decrease in WST-1 activity. Data shown are representative of two experiments.
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Research to develop anti-viral or anti-tumor therapies for cervical
cancer have focused on sophisticated technologies such as immuno-
therapy, gene therapy, and novel compounds. Although promising,
vulnerable populations in developing nations are unlikely to have ac-
cess to these costly therapies. However, the use of nutraceuticals, like
curcumin, may be an effective and low-cost alternative for the pre-
vention and treatment of certain diseases [9,10,14–16]. In view of
the promising data for curcumin as an effective anticancer [17] and
antiviral agent [17–19], we have developed an intravaginal cream(Vacurin-20), which is effective in eliminating HPV-associated cervi-
cal cancer cell lines. Furthermore, we show Vacurin-20 does not affect
non-cancerous cells in our in vitro experiments and in our in vivo
mouse model.
Here we first show an interesting mechanistic trend in four
HPV(+) cervical cell lines that harbor wild-type p53 [20,21].
Curcumin caused a rapid inhibition of the cancer-promoting protein
EGFR and a simultaneous induction of the cell cycle inhibitor p53
(Fig. 2). Curcumin also blocked phosphorylation of Rb at serine-780,
which inactivates this protein. This unleashed its cell cycle-inhibitor
property in HeLa and ME-180 cells (Fig. 2). In contrast, expression
Fig. 5. Vacurin-20 treatment suppresses EGF receptor expression in the HeLa cells and does not cause a change in body weight or mucosal injury or inflammation in the lower re-
productive tract of treated mice. HeLa cells grown in 6-well plates were treated in duplicate wells with Vanicream or Vacurin-20 applied from membrane inserts for 8 h in
serum-free medium. The cells did not appear stressed after this short treatment, but were lysed and subjected Western blot analysis to measure EGFR expression. (a) A marked
decrease in EGFR expression was observed even after this brief treatment. (b) Quantification of peak intensities showed that EGFR expression was significantly less in the
Vacurin-20-treated wells (pb0.05; n=2). (c) Four female mice in each group were intra-vaginally infused with about 10 μL of either Vanicream alone or Vacurin-20 per day for
3 weeks. The mice were weighed before and after treatment. No significant change in body weight was observed after any treatment. (d) Three female mice in each group were
similarly infused with either PBS, or Vanicream, or Vacurin-20. After 3 weeks, the mice were sacrificed, saggital sections of the lower reproductive tract were stained with H&E.
High- and low-magnification (the inset) images from each group are shown. Each saggital section prepared from the cervical and vaginal regions was subjected to pathological
examination and the inferences are shown in Table 1. Compared to the PBS- and Vanicream-treated controls, Vacurin-20 treatment did not show any increased mucosal or stromal
inflammation or injury.
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Table 1
Histopathology of Lower Genital Tract of Treated Mice.
Intravaginal infusion Epithelial inflammation Stromal
inflammation (grade)
C1-PBS Grade 0 1
C2-PBS Grade 1 1
C3-PBS Grade 3 (distal vaginal canal) 1
Grade 1–2 (proximal)
Vanicream1 Grade 0 1
Vanicream2 Grade 0 1
Vanicream3 Grade 1 (distal vaginal canal) 1
Grade 2 (cervix)
Vacurin-1 Grade 1 2
Vacurin-2 Grade 1 1
Vacurin-3 Grade 1–2 1
Grade 0 — no inflammatory cells present.
Grade 1 — mild acute inflammation with local areas containing neutrophils.
Grade 2 — moderate inflammation with diffuse areas containing neutrophils.
Grade 3 — severe inflammation with marked areas of inflammatory cells present with
focal areas of necrosis,
Grade 4— significant areas of necrosis and inflammation and/ormicro-abscess formation.
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ME-180, and the P–Rb/Rb ratio was too small even in the absence of
curcumin to cause any appreciable inactivation of Rb in these cell
lines (Fig. 2b). So, the curcumin-evoked cell cycle regulation in SiHa
and SW756 cells was likely to be caused through the induction of
p53 and inhibition of EGFR.
Earlier studies have used anHPV16-transformed human keratinocyte
cell line to show that wild type p53 causes suppression of Sp1- and Yin
Yang 1 (YY1)-mediated induction of EGFR [32]. Curcumin treatment
causes an induction of p53 in many cancer cell types [33–36] and this
increased p53 could cause suppression of EGFR in the four human cervi-
cal cancer cell lines used here. Additionally, curcumin,which inhibits his-
tone deacetylase (HDAC) [34,35], could block HDAC-mediated induction
of EGFR [33].
The HPV 16 oncoprotein E6, which has been implicated in
HPV-mediated transformation of normal cells, is dramatically suppressed
by curcumin. The transforming antigens E6 and E7, which complex with
p53 and Rb, respectively, trigger degradation of these cell cycle inhibitors
[37,38]. Thus, in addition to eliminating the HPV-infected cervical cancer
cells, by suppressing E6 (and possibly E7) and simultaneously boosting
p53 and activating Rb [17] (Fig. 2), curcumin may also block
HPV-associated transformation of cervical cancer cells. Further experi-
mentswill reveal if curcumin and Vacurin-20 are effective in suppressing
or eliminating other key regulatory HPV proteins like E2, which are
essential for viral replication [37,39]. This submits an exciting possibility
for the treatment of women with persistent HPV infection who are
known to be at high risk for developing severe dysplasia and cancer.
Furthermore, topical imidazoquinolines like Aldara, are able to stimulate
the immune response and improve antiviral immunity. [40]. In clinical
trials, these medications in some patients were to clear HPV infection
and cause regression of high grade vulvar and cervical dysplasias.
[7,41]. Combining these agents to enhance cell-mediated immunity
with our curcumin cream to modulate intracellular signaling, could be
an attractive approach to target several mechanisms that HPV uses to
evade host responses.
The commercially available base Vanicream is free of perfume,
lanolin, formaldehyde, parabens, or dyes [36]. It has been used earlier
to deliver steroid hormones to the vaginal area [4]. Data presented
here establish that our formulation, Vacurin-20, suppresses the
same pro-cancer signaling pathways as inhibited by curcumin and
effectively eliminates apposed cervical cancer cells. Through mouse
studies, we show here that intravaginal application of Vacurin-20 is
feasible and safe. The simplicity and inexpensive nature of this strat-
egy is the most important aspect of our research, as this approach isapplicable to both developed and developing nations. Its future as a
treatment modality for cervical cancer and HPV associated dysplasias
is currently being investigated through carefully designed clinical
trials. Successful development of a nutraceutical-based cream for
clinical use will depend on its stability, ease of application, and reli-
able anticancer and antiviral properties.
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